Nam Duoc JSC

Nam Duoc maintains a strong liquidity position with a current ratio of 2.56, indicating the company can cover its short-term liabilities more than twice over. The company holds VND 50 billion in cash and equivalents, and its operating cash flow of VND 104.7 billion supports ongoing operations without reliance on long-term debt, which is currently zero. Profitability metrics show a return on equity (ROE) of 13.86% and a return on assets (ROA) of 10.99%, both exceeding the typical thresholds for the pharmaceutical industry. These figures suggest efficient use of equity and assets to generate profit, aligning with the industry's preference for high ROIC and margin sustainability. The company's revenue is primarily concentrated in Vietnam, with disclosed operations in pharmaceutical manufacturing, traditional medicine, and related services. No significant geographic diversification is reported, and the company's exposure to domestic market conditions is high. Segment-wise, the pharmaceutical manufacturing and traditional medicine segments are the primary contributors to revenue. Looking ahead, the company is projected to maintain a stable growth trajectory, with no immediate signs of revenue contraction. Historical revenue growth and the absence of dilution risks support a conservative outlook for the next fiscal year. The company's capital expenditure of VND -27.25 billion indicates a focus on cost management rather than aggressive expansion. Risk factors for Nam Duoc are currently low, with no immediate liquidity or dilution concerns. The company's debt-to-equity ratio is zero, and there are no signs of near-term equity issuance or share dilution. The absence of long-term debt and strong cash reserves further reduce financial risk. Recent filings and transcripts do not indicate any material changes in the company's operations or strategy. The company continues to focus on its core pharmaceutical and traditional medicine segments, with no disclosed plans for major restructuring or new market entry.